Furthermore, the administration of STING reinstated the BRCA1-deficient breast cancer’s sensitivity to the PARP inhibitor.600 In certain tumors characterized by DNA repair deficiencies, the therapeutic efficacy of this combination can be further magnified. This evidence concerns the gene BRCA1 and breast cancer.